CJC-1295 + Ipamorelin
What Is the CJC-1295 & Ipamorelin Blend?
The CJC-1295 + Ipamorelin blend is a peptide combination widely examined in scientific research focused on growth hormone (GH) signaling and endocrine regulation.
CJC-1295 functions as a long-acting analog of growth hormone–releasing hormone (GHRH), extending GHRH activity in experimental models.
Ipamorelin is a highly selective ghrelin receptor (GHS-R1a) agonist, studied for its ability to stimulate GH release with minimal activity at other pituitary hormone pathways.
Researchers investigate this combination to better understand growth hormone pulsatility, IGF-1 signaling, and downstream metabolic effects in controlled laboratory settings.
Certificate of Analysis
Third-party tested for 99% purity
CJC-1295 + Ipamorelin Overview
The CJC-1295 + Ipamorelin blend combines two peptides extensively studied for their complementary roles in growth hormone release and IGF-1 pathway activation.
CJC-1295 is associated in research with sustained GH and IGF-1 signaling due to its extended half-life compared to native GHRH fragments.
Ipamorelin selectively stimulates GH release while demonstrating minimal effects on cortisol and prolactin in preclinical and clinical research.
When evaluated together, these peptides are commonly explored in models related to tissue recovery, body composition signaling, metabolic balance, and aging-related endocrine dynamics.
Teichman SL et al., 2006History and Development
The pairing of CJC-1295 and Ipamorelin originates from parallel advances in peptide endocrinology research.
CJC-1295 was developed in the early 2000s as a stabilized GHRH analog to overcome the rapid degradation of endogenous GHRH, enabling prolonged investigation of GH and IGF-1 pathways.
Ipamorelin, developed in the 1990s, emerged from research into ghrelin mimetics and was distinguished by its high selectivity for GH release, with limited off-target hormonal effects.
Together, these peptides became of interest for laboratory research into growth hormone regulation, recovery signaling, and metabolic processes.
Svensson J et al., 1998CJC-1295 Structure
Ipamorelin Structure
Research Findings
CJC-1295 and Ipamorelin have been examined across endocrine, metabolic, regenerative, and systemic research models. Published studies explore their influence on growth hormone signaling, IGF-1 activity, tissue recovery mechanisms, and cellular viability.
Key Areas of Investigation
- Endocrine: Growth hormone pulsatility, IGF-1 signaling pathways
- Metabolic: Lipid metabolism, lean tissue signaling, glucose balance
- Cellular: Proliferation, repair processes, recovery signaling
- Systemic: Cardiovascular relevance, tissue viability, healing dynamics
Collectively, these findings suggest broad experimental utility for the CJC-1295 + Ipamorelin combination. By modulating GH signaling while maintaining hormonal selectivity, this blend provides a versatile research platform for studying regeneration, resilience, and physiological balance in laboratory models.
Teichman SL et al., Journal of Clinical Endocrinology & Metabolism, 2006
